Pyelonephritis
Conditions
Interventions
Group 1: Pregnant patients diagnosed with pyelonephritis with indication for treatment with intravenous antibiotics (e.v.), according to the clinical protocol of the local hospital (cefuroxime 750 mg
D02.065.884.725.300
Sponsors
Faculdade de Ciências Farmacêuticas de Ribeirão Preto
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Pregnant women over the age of 18 will be investigated, diagnosed with pyelonephritis and with indication for treatment with antibiotics, seen at HC-FMRPUSP. Additionally, healthy pregnant patients will be recruited at the Women's Health of Ribeirão Preto-Mater (CRSMRP-Mater) and in the following basic units of health and municipal community medical centers Centro Médico Social Comunitário Vila Lobato; CSE Ipiranga / Dr Edgard Aché; UBS Dom Mielle / Prof. Dr. Aymar Baptista Prado; UBS Jardim Presidente Dutra / Dr. Sérgio Botelho da Costa Moares; USD Maria Casagrande Lopes / Ernesto Che Guevara; USF Vila Albertina / Dr. Álvaro Panazzolo; UBS Vila Tibério / Wilma Delphina by O. Garotti; UBS Bonfim Paulista / Mamoro Kobayashi and UBS Santa Cruz / Helio Lourenço de Oliveira and healthy non-pregnant volunteers from the Campus of the University of São Paulo, Campus of Ribeirão Preto. Pregnant patients of both protocols will be included in the study during the second and third quarters of the gestation
Exclusion criteria
Exclusion criteria: Pregnant women diagnosed with pyelonephritis will be excluded from the study when present at least one of the following diseases: chronic renal failure, syndromes hypertensive (chronic arterial hypertension and / or pre-eclampsia), chronic fetal distress and systemic lupus erythematosus. Healthy pregnant women and healthy non-pregnant volunteers will be excluded from the protocol when using OAT-inhibiting / inducing drugs, which may interact with furosemide or probenecid: amino salicylic acid, para-aminohipuric acid, citalopram, cholestyramine, escitalopram, diclofenac, digoxin , lithium, linezolid, rifampin, rifabutin, rifapentin, sertraline and teriflunomide.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In the group of pregnant women diagnosed with pyelonephritis, it is expected to find a difference between phases of at least 30% in the parameter area under the plasma concentration versus time curve of furosemide. On healthy pregnant women group, is expected to find a difference between phases of at least 50% in the area parameter under a furosemide plasma concentration versus time curve. On healthy non-pregnant women is expected to obtain the pharmacokinetic parameter area under a plasma concentration versus time curve of furosemide in this population for comparison with the pregnant groups. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are not expected. | — |
Countries
Brazil
Contacts
Public ContactJhohann Benzi
Outcome results
None listed